Creatine for the Brain: What the Menopause and Cognition Research Actually Shows

Creatine is the most studied supplement in the history of sports nutrition — more than 500 peer-reviewed papers, decades of use, and a safety record almost no other supplement can match. For most of that history, the conversation was about muscle: more power, more lean masslean mass Body weight that isn’t fat — mostly muscle, bone, and water., faster recovery.

That conversation has shifted. The interesting creatine research of the 2020s is increasingly about the brain — memory, mental fatigue, mood, and cognitive aging — and one of the populations showing up most often in that research is women, particularly women moving through perimenopauseperimenopause The transition period leading up to menopause — often several years — when hormone levels fluctuate and periods become irregular. Symptoms frequently begin here, before periods stop entirely. and menopause.

This is worth a careful look, because it’s a case where a familiar, cheap, well-tolerated compound is being pointed at problems people care about deeply: brain fog, word-finding trouble, low mood, and the slow cognitive changes that arrive with age. The science is real and moving in a consistent direction. It’s also younger and thinner than the marketing implies. Here’s what the evidence actually supports.

---

Why the Brain Is a Logical Target for Creatine

Creatine’s job in the body is energy buffering. Cells store energy as ATPATP (adenosine triphosphate) The molecule cells use as their direct energy currency. Nearly everything the body does — muscle contractions, brain activity, cellular repair — runs on ATP., but the ATP pool is small and turns over fast. The creatine–phosphocreatine system acts as a rapid-recharge battery: phosphocreatine donates a phosphate to regenerate ATP almost instantly when demand spikes.

The brain is an extreme case of high, fluctuating energy demand. It’s roughly 2% of body weight but consumes about 20% of resting energy, and that demand surges during effortful thinking, stress, and sleep deprivation. Anywhere energy supply can become a bottleneck, the phosphocreatine system matters — and the brain is exactly that kind of tissue.

This gives the brain hypothesis a coherent mechanism rather than a marketing story: if supplemental creatine can raise brain creatine stores, it could help the brain maintain performance when its energy budget is stretched. The key qualifier is if — brain creatine is harder to raise than muscle creatine, which is part of why dosing and study design matter so much here.

---

Why Women May Be a Special Case

One of the more underappreciated facts in this literature: women appear to store far less creatine than men to begin with. A 2021 review in Nutrients focused specifically on women’s health estimated that women have roughly 70–80% lower endogenous creatine stores than men, alongside differences in how creatine is metabolized across the menstrual cycle, pregnancy, and menopause.

That matters for two reasons. First, a lower baseline can mean more room to benefit from supplementation. Second, the hormonal transitions of perimenopause and menopause — when estrogen falls — overlap closely with the exact symptoms creatine is being studied for: mental fatigue, mood changes, low energy, and loss of muscle and bone. The same review highlighted that creatine’s effects on mood and cognition may be more pronounced in women, possibly because supplementation helps restore a pro-energetic state in the brain.

That’s a hypothesis, not a verdict. But it reframes creatine from “a supplement for male athletes” to a compound with a plausible, sex-specific rationale for midlife women — a group that has been chronically underserved by supplement research.

---

The 2026 Menopause Trial

The most direct test of this idea to date is the CONCRET-MENOPA trial, a randomized, double-blind, placebo-controlled study published in 2026 in the Journal of the American Nutrition Association. It enrolled 36 perimenopausal and menopausal women (mean age about 50) and compared placebo against several low-dose, highly soluble creatine formulations over 8 weeks.

The standout group received a medium dose of creatine hydrochloride (1,500 mg/day). Compared with placebo, that group showed improved reaction time, a roughly 16% increase in creatine concentration in the frontal lobe, and favorable shifts in blood lipids. There was also a signal toward reduced severity of mood swings, though it fell just short of statistical significance. Everything was well tolerated, with no serious side effects.

A few things are worth flagging honestly. This is a small trial — 36 women split across four groups — so each arm is tiny, and the findings need replication before anyone should treat them as settled. It also used creatine hydrochloride at a low dose, a more soluble form than the standard creatine monohydrate that the bulk of the evidence base rests on; the two are not interchangeable in the data. What the trial does establish cleanly is that a modest creatine dose measurably raised brain creatine in this population and moved a cognitive measure in the right direction. That’s a meaningful proof-of-concept, not a finished case.

---

What the Broader Cognition Evidence Shows

Zoom out from menopause to cognition generally, and the picture is “promising but uneven.”

A 2026 systematic review in Nutrition Reviews examined creatine and cognition specifically in older adults (55+). Across six studies and roughly 1,500 participants, five of the six reported a positive relationship between creatine and cognition — concentrated in the domains of memory and attention. The authors were candid about the limitation: only one study rated as methodologically “good,” and three rated “poor.” The honest summary is that the signal is consistent but the evidence quality is still low, and high-quality trials are needed.

A 2023 meta-analysis in the same journal pooled randomized trials of creatine and memory in healthy people and found an overall benefit, with a notably larger effect in older adults (66–76 years) than in younger people. This is frequently cited as strong evidence — but it deserves a note that’s usually omitted. A published letter to the editor argued that a statistical error (double-counting data from one study) may have inflated the result toward a false positive. The core finding — bigger benefit in older brains — is biologically plausible and echoed elsewhere, but this particular meta-analysis is not the slam-dunk it’s sometimes presented as.

---

Safety: One of the Best-Documented Profiles in the Supplement World

This is where creatine genuinely separates itself from most of the longevity supplement landscape. A 2021 expert review in the Journal of the International Society of Sports Nutrition systematically worked through the common fears, and the evidence is reassuring:

Kidney damage. In people with healthy kidneys, creatine at recommended doses does not cause kidney damage. The myth largely stems from creatine modestly raising serum creatinine — a lab marker — without actually impairing kidney function. People with existing kidney disease are a separate conversation and should talk to their physician.

Hair loss. This fear traces to a single 2009 study that found a rise in DHT (a hormone linked to hair loss) in college rugby players. It has never been replicated, and no study has actually shown creatine causes hair loss.

Dehydration, cramping, and “it’s a steroid.” None are supported by the evidence. Creatine is not an anabolic steroid; it does not cause dehydration or muscle cramping, and the water it draws is into muscle cells.

Mild GI upset can occur, usually at high single doses, and typically resolves by splitting the dose. The overall tolerability record across hundreds of studies is excellent.

---

Dosing: Keep It Simple

For the established muscle and bone benefits, the standard is 3–5 g/day of creatine monohydrate, taken consistently. A “loading phase” (around 20 g/day for 5–7 days) saturates stores faster but isn’t required — daily 3–5 g reaches the same place in a few weeks. Timing doesn’t meaningfully matter; consistency does.

The brain is the open question on dosing. Brain creatine is harder to raise than muscle creatine, and some researchers suspect higher doses or longer durations may be needed for cognitive effects — though the 2026 menopause trial saw brain creatine rise on a relatively modest dose. Until that’s clarified, a reasonable approach for someone primarily interested in cognition is the same 3–5 g/day of monohydrate, recognizing the brain effects are the less certain part of the equation.

A few practical points: creatine monohydrate is the form with by far the most evidence and the best value — the exotic, more expensive forms rarely justify their price. Look for a third-party quality certification (such as Creapure, NSF, or Informed Sport), since the supplement market has real quality variance and the FDA does not pre-approve products for purity.

---

Where This Leaves Us

Creatine occupies an unusual position. Its oldest, best-established benefits — muscle and bone, especially paired with resistance training and especially in older adults — are about as solid as supplement science gets. Its newest and most exciting application — the brain — is real, mechanistically sensible, and supported by a growing but still immature human literature.

For midlife women in particular, the convergence is striking: lower baseline creatine stores, accelerating muscle and bone loss after menopause, and early cognitive and mood signals all point the same direction. That doesn’t make creatine a treatment for menopausal brain fog or cognitive aging — the trials aren’t there yet. It makes it a low-risk, low-cost supplement with a strong floor of proven benefits and a plausible ceiling of cognitive upside that the science is actively working to confirm.

If you want to see where creatine ranks against the other evidence-tiered options like omega-3s and NAD+NAD+ (nicotinamide adenine dinucleotide) A molecule every cell needs to make energy and repair DNA. Levels decline with age. precursors, our Longevity Protocol lays them out side by side.

---

A note on the research pipeline: The creatine-and-cognition field is moving quickly, with larger trials now underway in aging and clinical populations. The strength of the brain evidence in 2026 is “consistent early signal,” and that label could change meaningfully over the next two to three years as better-powered studies report.